Abstract
High-dose therapy with autologous peripheral blood stem cell (PBSC) rescue is widely used for the treatment of malignant disease. CD34 selection of PBSC has been applied as a means of reducing contamination of the graft. Although CD34 selection results in a 2 to 3 log reduction in contaminating tumor cells without significantly delaying engraftment, many other types of cells are depleted from the CD34-enriched grafts and immune reconstitution may be impaired. In the present study, 31 cytomegalovirus (CMV)-seropositive patients who received myeloablative therapy followed by the infusion of CD34- selected autologous PBSC were assessed for the development of CMV disease in the first 100 days posttransplant. Seven patients (22.6%) developed CMV disease and 4 patients (12.9%) died from complications of their infection. In a contemporaneous group of 237 CMV-seropositive patients receiving unselected, autologous PBSC, only 10 patients (4.2%) developed CMV disease, with 5 deaths (2.1%). In a multivariate logistic regression analysis, the use of CD34-selected autologous PBSC after high-dose therapy was associated with a marked increase in the incidence of CMV disease and CMV-associated deaths.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4029-4035 |
| Number of pages | 7 |
| Journal | Blood |
| Volume | 94 |
| Issue number | 12 |
| State | Published - Dec 15 1999 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Increased incidence of cytomegalovirus disease after autologous CD34- selected peripheral blood stem cell transplantation. / Holmberg, Leona A.; Boeckh, Michael; Hooper, Heather; Leisenring, Wendy; Rowley, Scott; Heimfeld, Shelly; Press, Oliver; Maloney, David G.; McSweeney, Peter; Corey, Lawrence; Maziarz, Richard; Appelbaum, Frederick R.; Bensinger, William.
In: Blood, Vol. 94, No. 12, 15.12.1999, p. 4029-4035.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Increased incidence of cytomegalovirus disease after autologous CD34- selected peripheral blood stem cell transplantation
AU - Holmberg, Leona A.
AU - Boeckh, Michael
AU - Hooper, Heather
AU - Leisenring, Wendy
AU - Rowley, Scott
AU - Heimfeld, Shelly
AU - Press, Oliver
AU - Maloney, David G.
AU - McSweeney, Peter
AU - Corey, Lawrence
AU - Maziarz, Richard
AU - Appelbaum, Frederick R.
AU - Bensinger, William
PY - 1999/12/15
Y1 - 1999/12/15
N2 - High-dose therapy with autologous peripheral blood stem cell (PBSC) rescue is widely used for the treatment of malignant disease. CD34 selection of PBSC has been applied as a means of reducing contamination of the graft. Although CD34 selection results in a 2 to 3 log reduction in contaminating tumor cells without significantly delaying engraftment, many other types of cells are depleted from the CD34-enriched grafts and immune reconstitution may be impaired. In the present study, 31 cytomegalovirus (CMV)-seropositive patients who received myeloablative therapy followed by the infusion of CD34- selected autologous PBSC were assessed for the development of CMV disease in the first 100 days posttransplant. Seven patients (22.6%) developed CMV disease and 4 patients (12.9%) died from complications of their infection. In a contemporaneous group of 237 CMV-seropositive patients receiving unselected, autologous PBSC, only 10 patients (4.2%) developed CMV disease, with 5 deaths (2.1%). In a multivariate logistic regression analysis, the use of CD34-selected autologous PBSC after high-dose therapy was associated with a marked increase in the incidence of CMV disease and CMV-associated deaths.
AB - High-dose therapy with autologous peripheral blood stem cell (PBSC) rescue is widely used for the treatment of malignant disease. CD34 selection of PBSC has been applied as a means of reducing contamination of the graft. Although CD34 selection results in a 2 to 3 log reduction in contaminating tumor cells without significantly delaying engraftment, many other types of cells are depleted from the CD34-enriched grafts and immune reconstitution may be impaired. In the present study, 31 cytomegalovirus (CMV)-seropositive patients who received myeloablative therapy followed by the infusion of CD34- selected autologous PBSC were assessed for the development of CMV disease in the first 100 days posttransplant. Seven patients (22.6%) developed CMV disease and 4 patients (12.9%) died from complications of their infection. In a contemporaneous group of 237 CMV-seropositive patients receiving unselected, autologous PBSC, only 10 patients (4.2%) developed CMV disease, with 5 deaths (2.1%). In a multivariate logistic regression analysis, the use of CD34-selected autologous PBSC after high-dose therapy was associated with a marked increase in the incidence of CMV disease and CMV-associated deaths.
UR - http://www.scopus.com/inward/record.url?scp=13044276241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13044276241&partnerID=8YFLogxK
M3 - Article
C2 - 10590046
AN - SCOPUS:13044276241
VL - 94
SP - 4029
EP - 4035
JO - Blood
JF - Blood
SN - 0006-4971
IS - 12
ER -